专利检索 cpc:"Y02A50/411" 第 3 页

21.

发明授权
Desferrithiocin analogs and uses thereof 有权

公开(公告)号：US10010535B2

公开(公告)日：2018-07-03

申请号：US15038188

申请日：2014-11-21

申请人： University of Florida Research Foundation, Incorporated

发明人： Raymond J. Bergeron, Jr.

IPC分类号： A61K31/426 , A61K31/4439 , C07D277/12 , C07D417/04 , C07H15/26

CPC分类号： A61K31/426 , A61K31/4439 , C07D277/12 , C07D417/04 , C07H15/26 , Y02A50/411

摘要： Iron overload is associated with pathological conditions such as oxidative stress, transfusional iron overload, thalassemia, primary hemochromatosis, secondary hemochromatosis, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, and reperfusion injury. The present invention provides methods and pharmaceutical compositions using desferrithiocin analogs of Formulae (A) and (J) for treating and/or preventing these pathological conditions, metal (e.g., iron, aluminum, a lanthanide, or an actinide (e.g., uranium)) overload conditions, and infectious diseases (e.g., malaria).

22.

发明申请
Method and Medicament For Inhibiting The Expression of A Given Gene 审中-公开

公开(公告)号：US20180179526A1

公开(公告)日：2018-06-28

申请号：US15870380

申请日：2018-01-12

申请人： Alnylam Pharmaceuticals, Inc.

发明人： Roland Kreutzer , Stefan Limmer

IPC分类号： C12N15/113 , C12N15/11

CPC分类号： C12N15/113 , A61K31/713 , A61K38/00 , C12N15/111 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2330/30 , Y02A50/411 , Y02A50/467

摘要： The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.

23.

发明授权
Methods for production of platelets from pluripotent stem cells and compositions thereof 有权

公开(公告)号：US09993503B2

公开(公告)日：2018-06-12

申请号：US14515619

申请日：2014-10-16

申请人： Astellas Institute for Regenerative Medicine

发明人： Qiang Feng , Shi-Jiang Lu , Robert P. Lanza

IPC分类号： A61K35/19 , C12N5/078

CPC分类号： A61K35/19 , C12N5/0644 , C12N2501/04 , C12N2501/20 , C12N2501/2306 , C12N2501/2309 , C12N2501/2311 , C12N2501/30 , C12N2501/40 , C12N2501/727 , C12N2501/734 , C12N2501/91 , C12N2506/11 , Y02A50/411

摘要： Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

24.

发明授权
Pharmaceutical formulations of HDAC inhibitors 有权

公开(公告)号：US09957227B2

公开(公告)日：2018-05-01

申请号：US15813582

申请日：2017-11-15

申请人： TopoTarget UK Limited

发明人： Richard J. Bastin , Nicholas J. Hughes

IPC分类号： C07C311/21 , A61K47/18 , A61K47/40 , A61K31/18 , A61K9/00

CPC分类号： C07C311/21 , A61K9/0019 , A61K31/18 , A61K47/18 , A61K47/183 , A61K47/40 , Y02A50/411

摘要： This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxyl-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

25.

发明授权
Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient 有权

公开(公告)号：US09925274B2

公开(公告)日：2018-03-27

申请号：US14443166

申请日：2013-11-01

申请人： Sapiotec GmbH

发明人： Norbert Roewer , Jens Broscheit

IPC分类号： A61K31/7048 , A61K47/40 , A61K47/48 , A61K9/08 , A61K9/14 , A61K31/724 , A61K45/06 , A61K31/353 , A61K31/352 , A61K47/69

CPC分类号： A61K47/6951 , A61K9/08 , A61K9/146 , A61K31/352 , A61K31/353 , A61K31/724 , A61K45/06 , A61K47/40 , Y02A50/411 , A61K2300/00

摘要： The invention relates to a composition comprising a complex of delphinidin and a sulfoalkyl ether β-cyclodextrin for use as an antiphlogistic and/or immunosuppressive.

26.

发明申请
METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS 审中-公开

公开(公告)号：US20180071279A1

公开(公告)日：2018-03-15

申请号：US15815426

申请日：2017-11-16

申请人： The General Hospital Corporation

发明人： Vamsi K. Mootha , Vishal Gohil , Sunil Sheth , Yuhua Ji

IPC分类号： A61K31/495 , A61K45/06 , G01N33/50 , A61K31/382 , A61K31/55 , A61K31/5415 , A61K31/496

CPC分类号： A61K31/495 , A61K31/382 , A61K31/496 , A61K31/5415 , A61K31/55 , A61K45/06 , C12Y207/07014 , G01N33/502 , G01N2333/9125 , Y02A50/411 , Y02A50/414

摘要： Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.

27.

发明申请
COMPOSITIONS AND METHODS FOR INCREASING LIFESPAN AND HEALTH SPAN 审中-公开

公开(公告)号：US20180055896A1

公开(公告)日：2018-03-01

申请号：US15482894

申请日：2017-04-10

申请人： Generex Pharmaceuticals, Inc.

发明人： Ming Li , Lei Cheng

IPC分类号： A61K36/00 , A61K31/565 , A61K31/7028 , A61K31/7032 , A61K31/7034 , A61K31/56 , A61K36/23 , A61K36/73

CPC分类号： A61K36/00 , A61K31/56 , A61K31/565 , A61K31/7028 , A61K31/7032 , A61K31/7034 , A61K36/23 , A61K36/73 , A61K2300/00 , Y02A50/411

摘要： Disclosed herein are compounds, extracts, and active fractions of the plant Geum japonicum and methods for increasing longevity and survival potency or for preventing or treating various medical conditions, including diabetes, inflammation, wound healing, bed sores, and ocular disorders. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided are the use of the compounds and extracts in preparing pharmaceutical formulations and medicaments

28.

发明授权
Anti-inflammatory omega-3 synergistic combinations 有权

公开(公告)号：US09901562B2

公开(公告)日：2018-02-27

申请号：US14782583

申请日：2014-03-04

申请人： LYCORED LTD.

发明人： Rachel Levy , Nurit Hadad , Tanya Sedlov , Morris Zelkha , Masha Sapojnik

IPC分类号： A61K31/202 , A61K31/01 , A61K9/00 , A61K31/047 , A61K31/355 , A61K36/81 , A61K31/192 , A61K31/035

CPC分类号： A61K31/202 , A61K9/0053 , A61K31/01 , A61K31/035 , A61K31/047 , A61K31/192 , A61K31/355 , A61K36/81 , Y02A50/411 , A61K2300/00

摘要： This invention is directed to compositions having synergistic combinations of omega-3 fatty acid such as OMEGA-3 with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.